News
-
Hovione has acquired a formulation facility located next to its existing Loures, Portugal facility for process chemistry and particle engineering, the company said. The new facility will be able to produce clinical trial supplies and… Read more . . .
-
The first patients have been dosed in a Phase 2a study of Verona Pharma’s RPL554 inhaled PDE3/PDE4 inhibitor as an addition to albuterol (salbutamol) and with ipratropium for the treatment of COPD, Verona said. The… Read more . . .
-
Impel NeuroPharma has announced that 3M New Ventures (3M NV) led the investment in its $12 million Series B financing round to raise money for commercialization of Impel’s Precision Olfactory Delivery (POD) platform. Impel recently… Read more . . .
-
Grupo Ferrer, which is partnered with Alexza Pharmaceuticals on Adasuve Staccato loxapine inhalation powder in the EU, Latin America, CIS nations, Middle East, North Africa, and parts of Asia, has reiterated its support for the… Read more . . .
-
Hovione has announced that Kristine Senft has joined the company as VP, Sales and Marketing and will succeed Dave Hoffman as VP, Sales and Business Development upon his retirement in April 2016. Senft, who was… Read more . . .
-
Eli Lilly has acquired worldwide rights to Locemia Solution’s intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder… Read more . . .
-
OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products.… Read more . . .
-
InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company’s inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No.… Read more . . .
-
3M Drug Delivery Systems and Impel NeuroPharma have announced that the two companies will collaborate on development and commercialization of Impel’s Precision Olfactory Delivery (POD) platform for intranasal delivery of drugs to the central nervous… Read more . . .
-
Serendex Pharmaceuticals has announced that data from a Phase 1 randomized, double blind, placebo controlled single ascending dose/multiple ascending dose trial showed that Molgradex inhaled GM-CSF (molgramostim) was well tolerated at all dose levels. No… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany